Case Study Interprets Continuous Process Verification Guidance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Case Study Interprets Continuous Process Verification Guidance


BioPhorum Operations Group (BPOG) has published a resource to help the biopharmaceutical industry deliver a high quality, consistent approach to continued process verification (CPV). The resource, a case study developed in response to Stage 3 process verification guidance from the FDA, is designed to help companies develop their own CPV approach by providing best practices and guidance on how to implement and demonstrate effective process validation.

The 100-page case study, “Continued Process Verification: An Industry Position Paper with Example Plan,” was written by subject matter experts from major biotech manufacturers. The document describes the thought processes behind the creation of a CPV plan.  Containing a model plan based on a generic monoclonal antibody (mAb) production process, the case study makes it clear how critical process parameters are identified, analyzed, and reported for every step in the process.

Source: BioPhorum Operations Group

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here